Health System Concerns Related to TasP and Most At Risk Populations. Example from the United Kingdom Impact of TasP on the MSM epidemic

Similar documents
HIV New Diagnoses, Treatment and Care in the UK 2015 report

HIV in the United Kingdom: 2014 Report

HIV prevention and the wider UK population. What HIV prevention work should be directed towards the general population in the UK?

HIV in the United Kingdom: 2013 Report

Estimates of New HIV Infections in the United States

Annual Epidemiological Spotlight on HIV in London 2014 data

Understanding the HIV Care Continuum

Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care

HIV Surveillance Update

Effective Integration of STI & HIV Prevention Programs

HPTN 073: Black MSM Open-Label PrEP Demonstration Project

Q and A for PARTNER Studies: Interim analysis results presented at CROI CROI presentation can be found at

THT BRIGHTON HEALTH PROMOTION: UTILISING ONLINE, MOBILE APPS & SOCIAL MEDIA

HIV Guidelines. New Strategies.

Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers

Infection report. Sexually transmitted infections 1 and chlamydia screening in England, HIV-STIs. Key messages and recommendations: Introduction

UNITED NATIONS GENERAL ASSEMBLY SPECIAL SESSION ON HIV/AIDS. Country Progress Report Sweden

HIV Epidemiology in New York State

HIV Prevention Needs Assessment for London

STOP HIV/AIDS Quarterly Monitoring Report

UNAIDS 2014 LESOTHO HIV EPIDEMIC PROFILE

WISCONSIN AIDS/HIV PROGRAM NOTES

GARPR Online Reporting Tool

EXPANDED HIV TESTING AND LINKAGE TO CARE (X-TLC) IN HEALTHCARE SETTINGS ON THE SOUTH SIDE OF CHICAGO

The HIV/AIDS Epidemic in California s Latino Population

Aim of Presentation. The Role of the Nurse in HIV Care. Global Epidemic 7/24/09

Global Update on HIV Treatment 2013: Results, Impact and Opportunities

STOP HIV/AIDS Quarterly Monitoring Report

M I L L I O N S Figure 2.1 Number of people newly infected with HIV

New Brunswick Health Indicators

Ending the Epidemic in New York State. Federal AIDS Policy Partnership March 4, 2015

HIV/AIDS Epidemic Status at-a-glance

Methodology Understanding the HIV estimates

Sexual health commissioning Frequently asked questions Published February Health, adult social care and ageing

HIV/AIDS Prevention and Care

HIV Testing Action Plan

HIV Continuum of Care Monitoring Framework 2014

Department of Veterans Affairs National HIV/AIDS Strategy Operational Plan 2011

2011 STI Annual Report

Maryland HIV Plan

Australian Federation of AIDS Organisations (AFAO) Primary Health Care Reform

Annual Surveillance Report 2014 Supplement

Potential impact of routine testing of patients with HIV indicator disease in preventing late HIV diagnosis

HIV treatment for overseas visitors

The Global Epidemics of HIV among Men Who Have Sex with Men: Time for Action

Georgia HIV/AIDS Surveillance Summary. Data Through December 31, 2010

HIV and AIDS in Bangladesh

How testing and treatment can stop HIV. Information for gay and bisexual men.

hiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Q&A on methodology on HIV estimates

EPIDEMIOLOGY OF HEPATITIS B IN IRELAND

Outpatient/Ambulatory Health Services

Ten Good Reasons to Be Concerned about the Human Papillomavirus (HPV) Vaccination Campaign

HIV/AIDS In the Houston Area

STATE OF THE HIV/AIDS EPIDEMIC IN CHARLESTON

Hepatitis C Infections in Oregon September 2014

Integrating Medical Care Coordination Services into HIV Clinic Medical Homes

The Basics of Drug Resistance:

Teenage Pregnancy Reduction Plan 2014 to 2017

HIV Therapy Key Clinical Indicator (KCI)

The Botswana Combination Prevention Project (BCPP)

ECDC GUIDANCE. HIV testing: increasing uptake and effectiveness in the European Union.

UNAIDS 2013 AIDS by the numbers

Moving Toward Reduced HIV Incidence: How the San Francisco Experience Can Inform National HIV/AIDS Strategy Implementation

Dublin Declaration. on Partnership to fight HIV/AIDS in Europe and Central Asia

The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011

SIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item May Hepatitis

Response to HIV/AIDS in Brazil, public health system strengthening and programmatic integration

The use of ARVs in HIV prevention and the case for optimizing the preventive impact of ART?

4/30/2013 HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS HPV CONTINUED

4/3/2012. Surveillance. Direct Care. Prevention. Quality Management

Injection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results

Syphilis on the rise again in Germany results from surveillance data for 2011

Report: January 2012 Hepatitis C and HIV Co-infection

The use of alcohol and drugs and HIV treatment compliance in Brazil

XVIIth International Aids Conference, Mexico City

QUESTIONS & ANSWERS: PREVENTION OF SEXUALLY TRANSMITTED AND BLOOD BORNE INFECTIONS AMONG OLDER ADULTS PROTECTING CANADIANS FROM ILLNESS

THIS IS AN OFFICIAL NH DHHS HEALTH ALERT

Hepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System

Condoms for the prevention of HIV and STI transmission

2004 Update. Sierra Leone

FAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.

Program Performance Indicators Revised Baseline & Target Setting Form January 1 June 30, 2004 Interim Progress Report

The Ryan White CARE Act 2000 Reauthorization

Case Finding for Hepatitis B and Hepatitis C

UNAIDS ISSUES BRIEF 2011 A NEW INVESTMENT FRAMEWORK FOR THE GLOBAL HIV RESPONSE

Using data and tools to inform resource allocation for the HIV response. Dr. Sarah Alkenbrack & Dr. Suneeta Sharma Futures Group

Teenage Pregnancy and Sexual Health Marketing Strategy November 2009

EXECUTIVE SUMMARY: INTEGRATED EPIDEMIOLOGIC PROFILE FOR HIV/AIDS PREVENTION AND CARE ELIGIBLE METROPOLITAN AREA PLANNING, PHILADELPHIA

Sexually Transmitted Infections (STIs) and the STI Clinic

Health Issues Affecting Older Gay, Lesbian and Bisexual People in the UK

REPORTING CHANGES FOR 2014 NYSDOH AIDS INSTITUTE. Changes to Content and Priorities

Targeted HIV Testing & Enhanced Testing Technologies. HIV Prevention Section Bureau of HIV/AIDS

Guidelines for Preventative Health Care in LGBT Populations

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid

Minnesota HIV/AIDS Epidemiologic Profile

A guide for people with genital herpes

NURSE LED SERVICES IN CARDIFF AND VALE NHS TRUST. Sandra Smith Senior Nurse Manager Cardiff and Vale NHS Trust 28 th June 2007

AN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS

Transcription:

Health System Concerns Related to TasP and Most At Risk Populations Example from the United Kingdom Impact of TasP on the MSM epidemic Dr Valerie Delpech

Context Population of 60.5 million NHS provides free and open access HIV & STI care 200 HIV clinics & 240 STI clinics Robust surveillance and monitoring system of all newly diagnosed and persons accessing HIV care and treatment 100,000 living with HIV in 2012, 26% undiagnosed Cumulative 27,000 AIDS diagnoses, 20,000 deaths Overall prevalence is low 0.15% prevalence Epidemic concentrated in MSM, Africans communities & persons who inject drugs

Number of new HIV and AIDS diagnoses and deaths New HIV Diagnoses New HIV and AIDS diagnoses and deaths United Kingdom 9000 8000 7000 6000 HIV test developed New HIV diagnoses AIDS diagnoses Deaths HAART available 4500 4000 3500 New HIV diagnoses by exposure group MSM Heterosexual infected within the UK Heterosexual infected abroad IDU Other exposure categories 5000 3000 4000 2500 3000 2000 1500 2000 1000 1000 500 0 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

HIV care and treatment, UK Integration into HIV care following HIV diagnosis: First CD4 count reported by exposure group: UK, 2010 Access to HIV care in the UK is excellent >95% in care within 3 months > 95% retained in care annually 900 million spent on HIV treatment in 2010/11 ( 13,900 for each patient) HoL report calls from a refocus on HIV prevention 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% Within 2 weeks 2 weeks to 1 month 1 month to 3 months More than 3 months 0% Men who have sex with men Heterosexual men Heterosexual women People who inject drugs Other All Exposure groups

Proportion of people receiving ART Proportion of persons with a CD4 count <350 cell per mm 3 receiving antiretroviral therapy (ART) by exposure group: UK, 2010 2006 2008 2010 100% 90% 80% 70% 84% 79% 73% 91% 86% 81% 86% 85% 86% 87% 80% 81% 76% 72% 74% 60% 50% 40% 30% 20% 10% 0% Men who have sex with men Heterosexual men Heterosexual women Exposure group People who inject drugs All

Late HIV diagnoses (CD4 <350 cells/mm 3 ) in Europe 2010

Late diagnoses of HIV (<350 cells/mm 3 ) by exposure group: United Kingdom

500,000+ MSM (3.4% of the adult male population) HIV epidemic in MSM living in the UK New HIV diagnoses in MSM, UK 40 000 MSM living with HIV, 26% undiagnosed 9% prevalence in London, 3% outside 80% of diagnosed MSM on ART, 84% of MSM with CD4<350 HIV tests in MSM at STI clinics Access to & retention in care >95% throughout period Background of increasing STIs

Number of diagnoses STIs in MSM, UK Experienced largest increase in new infections (all age groups) in 2011* Improved and increased testing Ongoing unsafe sexual behaviour HIV transmission and STI outbreaks (e.g. LGV, Shigella) 8000 7000 6000 5000 4000 3000 Syphilis Gonorrhoea Genital herpes Chlamydia Genital warts 2000 1000 0 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Year Men who have sex with men: New STI diagnoses (GUM), 2002-2011, England * For cases in men where sexual orientation was recorded. LGV: lymphogranuloma venereum

1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 HIV epidemic in MSM, UK Despite high ARV coverage and retention in care.. Year on year increase in new diagnoses >3,000 in 2010, >25% are recently acquired (RITA) 3500 3000 New diagnoses 2500 2000 1500 1000 500 0 Impact of testing HIV Testing >85% in STI clinics 3.7 fold increase in testing from 16,000 in 2001 to 59,300 in 2010 MSM accepting a test increased from 58% to over 90% In 2010, estimated 15-25% of all MSM aged 15-59 tested

No evidence of a decline in HIV incidence Results of a multi-state model for population-level CD4 progression, leading to HIV and AIDS diagnoses, Birrell et al Annual HIV incidence in MSM, 2001-2010, England & Wales Back calculation approach based on CD4 count at diagnosis & AIDS Estimates both infection and diagnosis rates High incidence rates Decrease in time-to-diagnosis Findings consistent with other incidence models (Presanis & Phillips)

Undiagnosed infections in MSM; England & Wales 2001-2010, Birrell et al

TasP among MSM in the UK Despite substantial progress of test and treat prevention policies over the past decade in the UK, there is no evidence of a reduction in the incidence of HIV infection in MSM Failure of TasP? Why? Brown et al Analyses of Infectivity (viral load >1500 copies/ml) among diagnosed & undiagnosed MSM. 35% (14,000) of 40,000 men were estimated to be infective in 2010, of whom 62% are undiagnosed, 33% diagnosed but untreated, and 5% on ART. Infective MSM among the diagnosed untreated population fell from 5,200 in 2006 to 4,600 in 2010 with only a modest decline in median VL

Distribution of infectives* among HIV-infected MSM, UK: 2010, Brown et al Extending ART to all MSM with CD4 counts <500 cells/mm 3 would reduce infectivity from an estimated 35% to 29% and, in combination with halving the undiagnosed, to 21%.

Number of HIV-infected MSM, and proportion infective* by diagnostic and treatment status and median viral load (with interquartile range): UK: 2010

Increased HIV incidence in MSM despite high levels of ARTinduced viral suppression: analysis of an extensively documented epidemic A.Phillips et al Modeling of HIV epidemic in MSM in the UK using a individual based simulation of transmission, progression and effect of ART Large range of surveillance data (1981-2010), Natsal and other behaviour data from variety of sources Individual-based stochastic computer simulation model Assumes all transmission take place via condomless anal sex with an infective partner Sexual behaviour modelled as the number of short (3 months) vs longterm partners

Phillips et al model fits Number diagnosed per year Number seen for care per year Number of deaths per year Number on ART per year Median CD4 count at diagnosis Proportion of men on ART with viral load <500

Phillips et al, 2012 Key Findings High incidence in early 1980s declined in response to condom use Incidence increased after the introduction of ART due to a modest rise in condomless sex (26%) In 2010, 48% (34-64) of new infections were acquired from undiagnosed men in primary infection, 34% other undiagnosed, 10% diagnosed ART naïve, 7% ART exp Incidence of HIV in MSM, UK (per 100 person-year) Proportion having condom-less anal sex in the past year

Counter factual scenarios (a) (b) (c) (d) (e) (a) ART never introduces (b) No condom use (c) ART at diagnosis from 2000 (d) Increased testing rates (e) Higher testing and ART at diagnosis (b) Cessation of all condoms in 2000 would have resulted in a 400% increase in incidence (e) A policy of higher (68% testing yearly) and testing and ART would have resulted in a 62% lower incidence

Conclusions Access to HIV testing and treatment coverage and care is excellent in the UK Despite this, there is no evidence of a reduction in the incidence of HIV infection in MSM, the group most at risk of acquiring HIV in the UK Undiagnosed remain source of 60%-80% transmissions 34-60% of transmission occur from men in primary HIV infection (first few months) Much high rates of testing are required to reduce late diagnoses However even with higher testing rates, test and treat policy will is be sufficient to eliminate transmission without other interventions Health Promotion remains key Safer sex campaigns and behavioural interventions Address structural and societal barriers which fuel the epidemic Role of partner notifcation needs expanding, Further research to assess public health benefit of PreP

MSM living with HIV by diagnosis, treatment and viral load status: UK, 2010 * Numbers were adjusted by missing information and rounded to the nearest 100. Viral load <50 copies/ml after HIV treatment initiation in the year of initiation.

Acknowledgements Conference organisers Andrew Phillips, Paul Birrell and Alison Brown HIV & GUM physicians and all those who contribute to HIV & STI surveillance Colleagues at the HIV &STI Department, HPA In particular Anthony Nardone, Alison Brown, Meaghan Kall, Adamma Aghaizu, Sariak Desai, Cuong Chau, Zheng Yin, Graeme Rooney, Alan Hunter, Alan Darbin, Rajani Raghu, Gwenda Hughes & Noel Gill

Thank-you www.hpa.org.uk